40 results about "Anticoagulant effect" patented technology

This invention discloses an arabinogalactan sulfate derived from *Streptococcus filamentosa*, its preparation method, and its applications, belonging to the fields of natural product chemistry and marine biological resource development technology. The technical solution includes an arabinogalactan sulfate derived from *Streptococcus filamentosa*, with a monosaccharide composition comprising arabinose, galactose, and rhamnose, the molar percentage of arabinose being not less than 70%; the main chain backbone is modified with natural sulfate groups, with the sulfate groups replacing at least one hydroxyl site of the arabinose residues. This invention, when applied to anticoagulation, exhibits good safety and a significant anticoagulant effect.

The invention relates to the technical field of medical materials, and particularly discloses a heparinized polycaprolactone coating as well as a preparation method and application thereof. The preparation method of the heparinized polycaprolactone coating comprises the following steps: adding poloxamer 188 into an MES buffer solution, adding heparin, uniformly stirring, then adding EDC and NHS, and stirring for 40-120 minutes to prepare an activated heparin solution; and dropwise adding the polycaprolactone solution into the activated heparin solution, reacting at room temperature for 90-180 minutes, then dissolving the conjugate into chloroform through rotary evaporation, washing with water, drying with anhydrous MgSO4, precipitating with methanol, filtering the precipitate, and drying in vacuum at 30-40 DEG C to obtain the polycaprolactone heparin. According to the prepared heparinized polycaprolactone coating, local release of heparin is remarkably reduced, and the continuous anticoagulation effect is achieved; and the anticoagulant activity of heparin is reserved, and the coating with good stability is obtained.

The application provides a use of a combination of metoclopramide and latanoprost for preparing an anticoagulant drug, and belongs to the technical field of biological medicines. It is accidentally found that the anticoagulant effect of patients with deep vein thrombosis combined with high intraocular pressure is improved after long-term continuous oral administration of metoclopramide. Thanks to this beneficial discovery, the application realizes good anticoagulant effect by applying the latanoprost liniment in a topical manner on the basis of oral administration of metoclopramide. The application is convenient to administer, has definite and sustained curative effect, and is safe and reliable. The application expands the optional range of anticoagulant drugs, and realizes better curative effect at the same time, and has outstanding technical advantages and wide popularization prospect.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

The invention discloses a blood sampler, and relates to the technical field of blood sampling. Comprising a blood collection piece, a flow guide piece is installed in the blood collection piece, and the flow guide piece is used for guiding blood to the bottom of the blood collection piece; the blood collection piece is sleeved with a lifting adjusting piece; a lifting isolation piece is mounted in the blood collection piece; the lifting isolation piece magnetically attracts the lifting adjusting piece; a puncture sampling piece is mounted on the blood collection piece; an anticoagulant is conveniently drained to the inner side of the drainage tube by utilizing the lifting isolation piece, and the flow guide piece can be used for draining blood, so that the blood can be conveniently and directly discharged from an anticoagulant solvent at the bottom of the blood collection tube during collection, and the anticoagulant effect is ensured; the problems that according to an existing blood sampler, direct anticoagulation drainage to a solvent is not convenient, clear liquid is not convenient to isolate, protect and separate, and butt joint is tedious through manual single-hand operation are solved.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

The invention relates to the technical field of anticoagulant coatings, and discloses an ePTFE membrane grafted with a heparin and aminated hyaluronic acid coating and a preparation method. According to the method for preparing the ePTFE membrane grafted with the heparin and aminated hyaluronic acid coating, a primer layer is formed on the surface of the ePTFE membrane in a plasma polymerization mode, and heparin and hyaluronic acid are chemically and covalently grafted on the primer layer, so that the surface of the membrane has long-term stability and an anticoagulation effect; the problems that in the prior art, reaction is complex, solvent residues easily exist, stability is poor, the anticoagulant effect is poor, and gaps are blocked are solved.

The invention discloses a preparation method of Panax stipuleanatus protein, which comprises the following steps: adding 0.01 mol / L NaOH solution with pH of 9 into Panax stipuleanatus powder, uniformly mixing, centrifuging at 4 DEG C, and taking filter residue; adding an ethanol solution with the volume concentration of 70-80% into the filter residues, extracting and centrifuging at 4 DEG C to take the filter residues, adding a NaCl solution with the mass concentration of 2-4% into the filter residues, extracting and centrifuging at 4 DEG C, taking the filter residues again, adding water into the filter residues, extracting and centrifuging at 4 DEG C, and taking supernate; the supernatant is dialyzed for 12-24 h at the temperature of 4 DEG C with a dialysis bag with the molecular weight cut-off of 10 kDa, inner filtrate is collected, freeze drying is conducted, then the panax stipuleanatus protein is prepared, anticoagulant activity detection is conducted on the panax stipuleanatus protein, and the protein has the good anticoagulant effect; the preparation method disclosed by the invention is simple to operate, provides a new way for preparing a novel anticoagulant drug, and has a wide application prospect.

The invention relates to a heparin anticoagulant pentasaccharide capable of neutralizing and adjusting half-life period as well as a preparation method and application of the heparin anticoagulant pentasaccharide. Comprising the following steps: (1) preparing heparin hexasaccharide; (2) preparing heparin anticoagulant hexasaccharide; and (3) preparing the heparin anticoagulant pentasaccharide capable of neutralizing and adjusting the half-life period. The heparin anticoagulant pentasaccharide provided by the invention is structurally similar to the unique ultra-low molecular weight heparin fondaparinux sodium in the current market, a biotin group is only introduced to an E glycosyl group at a non-reducing end, so that rapid neutralization can be effectively realized through avidin, and by introducing PEG (Polyethylene Glycol) connexons with different lengths, the heparin anticoagulant pentasaccharide can be rapidly neutralized. The prepared heparin anticoagulant pentasaccharide can adjust the half-life period of ultra-low molecular weight heparin. Therefore, the lasting time of the medicine effect of the ultra-low molecular weight heparin is prolonged, and the requirement of frequent administration is reduced. Therefore, the anticoagulant effect of the ultra-low molecular weight heparin is more controllable, the treatment risk is reduced, and the treatment effect is improved.

The invention discloses an anticoagulant active site of massa medicata fermentata fujianensis as well as a preparation method and application thereof, and belongs to the field of biological medicines. The massa medicata fermentata fujianensis is used for preparing anticoagulant drugs for the first time. The method comprises the following steps: soaking a fermented mass raw material with methanol, performing reflux extraction, and recovering a solvent under reduced pressure to obtain a total extract; and separating the total extract by adopting macroporous adsorption resin column chromatography to obtain a water part, a 30% methanol part, a 50% methanol part and a pure methanol part. Platelet aggregation detection results show that all the parts can inhibit ADP-induced platelet aggregation, and the anticoagulant effect of the 30% methanol part is most prominent and is similar to that of a positive drug. According to the preparation method of the anticoagulant active part of the massa medicata fermentata fujianensis, the anticoagulant active part in the massa medicata fermentata fujianensis can be effectively separated and enriched, and the obtained anticoagulant active part can be applied to preparation of anticoagulant drugs and has good industrial application prospects and clinical value.

This invention provides a gene encoding a coral-derived anticoagulant polypeptide and its applications, belonging to the field of bioactive peptide technology. The invention provides an anticoagulant polypeptide GcKuz1, which includes the mature peptide segment shown in SEQ ID No. 1. The polypeptide GcKuz1 of this invention exerts antithrombotic and anticoagulant effects by binding to KLKB1 in the thrombin system. This polypeptide does not cause hemolysis or cytotoxicity, and has no bleeding risk, exhibiting good biocompatibility. The anticoagulant polypeptide of this invention has therapeutic effects on thrombotic diseases, such as arterial thrombotic diseases, venous thrombotic diseases, and capillary thrombotic diseases.

The invention discloses a base material coated with an anticoagulant coating and a preparation method of the base material. The preparation method comprises the following steps: immersing a base material into a polyhydroxy polymer solution, and carrying out hydroxylation modification on the surface of the base material to prepare a base material 1; immersing the base material 1 into the multi-amino polymer solution, and fully reacting to prepare a base material 2; immersing the base material 2 into a polymer solution containing a coupling agent and carboxyl and / or sodium carboxylate groups, and fully reacting to prepare a base material 3; immersing a base material 3 into the multi-amino polymer solution, and fully reacting to prepare a base material 4; and immersing the base material 4 into a heparin sodium solution, and fully reacting to prepare the heparin-grafted anticoagulant coating. The prepared anticoagulant coating is good in uniformity, high in coverage degree, firm and lasting in anticoagulant effect, and the heparin grafting content on the surface of the material can be regulated and controlled according to actual clinical requirements.

The invention discloses an antibacterial and anticoagulant bioactive coating and a preparation method thereof, and relates to the technical field of biomedical materials. Comprising the following steps: step 1, adding chitosan into a solvent, and uniformly stirring to obtain a chitosan solution; adding a copper ion source, stirring and chelating to obtain a chitosan chelated copper ion compound solution; 2, tannic acid is added into the chitosan chelated copper ion compound solution, stirring and mixing are conducted, and a mixed solution is obtained; 3, a base material is immersed in the mixed solution, the pH of the mixed solution is adjusted to be alkaline, constant-temperature standing reaction is conducted, washing and drying are conducted, and a finished product with the bioactive coating is obtained. The medical instrument prepared by the method has good antibacterial and anticoagulant effects.

The application discloses an anti-heparin-antithrombin complex antibody and application thereof in a heparin drug anticoagulation effect detection method, and comprises an antibody molecule capable of combining with a heparin-antithrombin complex, a light chain variable region amino acid sequence of the antibody molecule is shown as SEQ ID NO:1, and a heavy chain variable region amino acid sequence is shown as SEQ ID NO:2. The antibody molecule can be prepared into a kit for detecting the anticoagulation effect of the heparin drug, and has the characteristics of simple operation, high sensitivity, good repeatability, wide linearity and the like, and is suitable for high-throughput testing of the anticoagulation effect of the heparin drug.

The invention belongs to the field of functional medical catheter preparation, and particularly relates to an antibacterial and anticoagulant dialysis catheter with a sodium alginate-graphene oxide coating and a preparation method of the antibacterial and anticoagulant dialysis catheter. The preparation method comprises the following steps: (1) mixing a graphene oxide dispersion liquid with a sodium alginate solution, then adding a water / alcohol mixed solvent, and then carrying out ultrasonic dispersion treatment to obtain a mixed solution; (2) performing plasma pretreatment on the polyurethane dialysis catheter to obtain a pretreated catheter; (3) immersing the pretreated conduit into the mixed solution, and after dip-coating is completed, sequentially standing and drying to obtain a primary gel layer conduit; and (4) immersing the primary gel layer catheter into a cross-linking solution, and then sequentially cleaning, gradient heating and curing. Efficient antibiosis and anticoagulation are achieved through the synergistic effect of materials, the coating is firm in combination and excellent in biocompatibility, the problems of thrombus formation, infection and the like of an existing dialysis catheter can be solved, and the coating is suitable for hemodialysis vascular access.

This application discloses a complex polysaccharide, its preparation method, and its applications. It discloses both a novel use of sulfated kudzu polysaccharide as a raw material for preparing drugs with anticoagulant effects and a complex polysaccharide comprising sulfated polysaccharide and polysaccharide fragments; wherein the sulfated polysaccharide includes sulfated kudzu polysaccharide and / or sulfated Bletilla striata polysaccharide; and the polysaccharide fragments include glycosaminoglycan fragments. This application modifies the structure of natural polysaccharides to improve their structural properties, preparing and screening complex polysaccharides with anticoagulant activity. The components in the complex polysaccharide work synergistically, significantly enhancing the anticoagulant effect and broadening the application fields of polysaccharides, primarily for the development of anticoagulant drugs and anticoagulant medical devices.

The utility model relates to the technical field of blood collection, in particular to a blood collection anti-coagulation device which comprises an outer frame body, an inner frame body, a working frame body and an anti-coagulation structure, the inner frame body is installed in the outer frame body in a sliding mode, the working frame body is installed in the inner frame body in a sliding mode, and the anti-coagulation structure comprises a driving body, a horizontal anti-coagulation assembly and a longitudinal anti-coagulation assembly. A driving body is installed at the bottom in the outer frame body, a horizontal anti-condensation assembly and a longitudinal anti-condensation assembly are sequentially and fixedly installed on the surface of the driving body, and the driving body synchronously drives the horizontal anti-condensation assembly and the longitudinal anti-condensation assembly to work, so that the inner frame body is driven to horizontally slide in a reciprocating mode, and the working frame body is driven to longitudinally horizontally move in a reciprocating mode; therefore, the anticoagulant can be uniformly distributed through longitudinal and transverse oscillation, the mixing effect of the anticoagulant and blood is improved, and the problem that the anticoagulant effect is affected due to the fact that the blood and the anticoagulant are easily mixed unevenly is solved.

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.

The invention provides a rare earth anticoagulant material for a venous pipeline and a preparation method and application thereof.The rare earth anticoagulant material is prepared from raw materials including ferulic acid and rare earth nitrate, the ferulic acid is a phenolic acid substance with the anti-oxidation, anti-inflammation and antibacterial effects, the chemical property of rare earth ions is quite similar to that of calcium ions, and the rare earth nitrate has the anti-oxidation, anti-inflammation and antibacterial effects. The rare earth ions are more than calcium ions by one positive charge, the ion charge density is higher than that of the calcium ions, and the rare earth ions have stronger combining capacity with oxygen-containing ligands and can competitively replace calcium to form a more stable complex, so that the protein structure is influenced, the normal blood coagulation process is destroyed, and the anticoagulation effect is achieved; the combination of the two can obtain a material with a better anticoagulant effect.

The invention discloses a nano drug delivery system and a preparation method and application thereof.The nano drug delivery system comprises nano particles, a platelet membrane, a tissue-type plasminogen activator and a thrombin specific aptamer, the nano particles are at least partially coated with the platelet membrane, and the thrombin specific aptamer is at least partially coated with the tissue-type plasminogen activator. The tissue-type plasminogen activator and the thrombin specific aptamer are connected to the platelet membrane. The nano drug delivery system disclosed by the invention has good targeting property, a rapid thrombolysis effect and a local anticoagulation effect, and is beneficial to avoiding secondary coagulation and reembolism risks.

The invention belongs to the technical field of biological medicine, and discloses application of an active substance in preparation of a VKOR inhibitor and / or a vitamin K antagonist and an anticoagulant drug. The invention provides application of an active substance shown in a formula (1) or pharmaceutically acceptable salt thereof in preparation of a vitamin K epoxide reductase inhibitor. The active substance has VKOR inhibitory activity, can prevent liver from synthesizing blood coagulation factors and activating anticoagulant factors by blocking reduction of oxidized vitamin K and inhibiting circulation of vitamin K, has potential anticoagulant activity, and has the advantages of mild anticoagulant effect, low probability of occurrence of adverse hemorrhage events, good anticoagulant effect, high safety and the like. The compound has a good application prospect in preparation of anticoagulants and / or medicines for treating thromboembolic diseases.

This application discloses a drug-coated stent and its preparation method, belonging to the field of medical devices. The drug-coated stent includes: a drug-coated stent substrate; an anticoagulant coating covering the surface of the drug-coated stent substrate; an intermediate coating covering the anticoagulant coating and located on the outer surface of the drug-coated stent substrate; and a drug coating coated on the outer surface of the intermediate coating, the drug coating comprising an active drug and a controlled-release polymer controlling the release rate of the active drug; the intermediate coating and the anticoagulant coating are bonded by electrostatic adsorption. The drug-coated stent provided by this application exhibits the following advantages: the anticoagulant coating stably exerts its anticoagulant effect and reduces the risk of thrombosis; the intermediate coating enhances the bonding strength between the drug coating and the anticoagulant coating and prevents its detachment; and the drug coating enables sustained release of the active drug and inhibits restenosis. These three components synergistically address both anticoagulant and anti-restenosis effects, improving the stent's therapeutic efficacy and clinical applicability. The preparation process is simple and controllable, suitable for large-scale production.

The invention provides a self-anticoagulation blood fat adsorbent as well as a preparation method and application thereof, and the preparation method of the self-anticoagulation blood fat adsorbent comprises the following steps: preparing macroporous resin with suspension double bonds on the surface; the preparation method comprises the following steps: under the action of a first initiator, carrying out grafting reaction on macroporous resin with a carboxyl-containing monomer, a sulfonic acid group-containing monomer and a hydroxyl-containing monomer at the same time to prepare the self-anticoagulation blood fat adsorbent, wherein the carboxyl group-containing monomer, the sulfonic group-containing monomer and the hydroxyl group-containing monomer all contain unsaturated double bonds. The self-anticoagulation blood fat adsorbent provided by the invention has good strength, not only has good adsorption performance on low-density lipoprotein, but also has a self-anticoagulation effect, can be directly used for whole blood perfusion, and is beneficial to improving the safety of blood purification.

The invention relates to the field of medical equipment, in particular to a blood compatible modification method and a modified hollow fiber membrane. The method comprises the following steps: immersing a matrix into a solution containing a polyphenol raw material, heating and oscillating to enable polyphenol to be self-polymerized on the surface of the matrix to introduce phenolic hydroxyl groups, immersing into a solution containing an anticoagulant polymer, taking out, and carrying out heat treatment to obtain a modified body. The anticoagulant polymer comprises a phosphorylcholine group, a hydrophobic block with hydrophobicity and an epoxy group, and the epoxy group is connected with a phenolic hydroxyl group through a chemical reaction, so that the phosphorylcholine group and the hydrophobic block are stably connected to the surface of a matrix. The phosphorylcholine group provides an anticoagulant effect, and the hydrophobic block provides pollution resistance, so that the modifier is not easy to pollute in a blood environment. After the hollow fiber membrane is modified, performance reduction caused by deposition of components such as thrombus and protein can be inhibited, so that the service life of a matrix is prolonged.

The invention discloses an MOFs-based blood perfusion adsorption material and a preparation method thereof, and relates to the technical field of blood perfusion, the adsorption material takes a melt-blown non-woven fabric as a matrix, in-situ growth of an adsorbent MOFs and heparin connected with an MOFs organic ligand in a covalent bond mode is carried out on the surface of the melt-blown non-woven fabric, the gram weight of the melt-blown non-woven fabric is 30-200g / m < 2 >, and the fiber diameter is 0.3-7.5 [mu] m. The hemolysis rate of the MOFs-based blood perfusion adsorption material is kept within 10%, the MOFs-based blood perfusion adsorption material has good biocompatibility, the selected melt-blown cloth base body has good biocompatibility and high porosity, part of protein binding elements with large particle sizes can be preliminarily screened out, the MOFs-based blood perfusion adsorption material shows excellent adsorption performance for various toxins in blood, and the MOFs-based blood perfusion adsorption material is suitable for being applied to various toxins in blood. The excellent anticoagulation effect is realized.

The invention provides a PMP hollow fiber membrane with an antithrombotic function and a preparation method of the PMP hollow fiber membrane. According to the method, a decahydronaphthalene / xylene low-temperature solvent system is constructed, PMP is uniformly dissolved under the condition that the temperature does not exceed 90 DEG C, and a thermal protective agent is adopted, so that the biological activity of hirudin in the processing process is effectively maintained; furthermore, oxidized chitosan is used as a controlled release carrier, and high load and slow release regulation of hirudin are realized through directional covalent coupling grafting of the zwitterionic polymer; finally, the physical barrier of the zwitterionic polymer and the direct anticoagulation effect of the hirudin are combined to construct a synergistic antithrombotic mechanism. On the premise of not depending on heparin, the obtained hollow fiber membrane has the comprehensive advantages that the blood coagulation time is remarkably prolonged, hirudin is released stably and durably, and HIT risks are avoided, is suitable for clinical scenes such as blood purification and in-vitro oxygenation, and has important clinical application value.

The application belongs to the field of medicine, and discloses a compound or a pharmaceutically acceptable salt, a stereoisomer, a solvate thereof, the structure of which is shown in formula I. In vitro binding efficacy experiments and toxicity experiments of low molecular heparin and the triazine compound of the application show that the triazine compound can produce good combination with low molecular heparin, and can reverse the anticoagulation of heparin, is a safe and low-toxic small molecule compound, and can be used for preparing a medicine for reversing the anticoagulation activity of heparin, treating and / or preventing adverse reactions and diseases caused by excessive heparin anticoagulation. The application discloses the use of the triazine compound or the pharmaceutically acceptable salt, the stereoisomer, the solvate thereof in preparing an anticoagulant reversing agent. The application discloses the use of the triazine compound or the pharmaceutically acceptable salt, the stereoisomer, the solvate thereof in preparing a medicine for treating side effects of excessive anticoagulation caused by using heparin to treat diseases, and preparing a medicine for treating surgical operations in which the anticoagulation activity of heparin needs to be reversed.

The application discloses an anticoagulant material, which is based on enzyme-like catalytic reaction to produce nitric oxide, dinitrogen trioxide, nitrous acid and / or other similar substances with anticoagulant function, so as to improve the anticoagulant effect of a blood-contacting medical device or medical material surface. The application also discloses related medical devices or medical materials, and preparation methods and uses thereof. The anticoagulant coating of the blood-contacting medical device surface provided by the application based on enzyme-like catalytic reaction to produce nitric oxide or similar substances has excellent service effect, and can solve the problems of poor biocompatibility, easy blood coagulation on the surface, and the need to cooperate with anticoagulant drugs with large side effects of the blood-contacting medical device for a long time.

The present invention belongs to the field of medical technology, and in particular to a method for improving the antithrombotic action time and safety of cationic polyphosphate inhibitors in vivo. The present invention specifically chemically modifies cationic polyphosphate inhibitors with human serum protein ligands to improve their antithrombotic action time and safety in vivo, wherein the human serum protein ligand is 2-carboxyl phthalocyanine zinc, and the cationic polyphosphate inhibitor is low molecular weight polyethyleneimine or polylysine. Experimental data show that 2-carboxyl phthalocyanine zinc coupling significantly improves the half-life and anticoagulant action time of low molecular weight polyethyleneimine and polylysine in mice, prevents thrombosis without causing bleeding side effects, and effectively reduces the acute toxicity of low molecular weight polyethyleneimine to mice and zebrafish. Thus, it can be used to develop antithrombotic drugs with broad application prospects.